

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/656,657	09/04/2003	David J. Burke	A-72167-1	8319	
32940	7590 09/23/2004		EXAM	EXAMINER	
DORSEY & WHITNEY LLP			YOUNG, MICAH PAUL		
INTELLECTUAL PROPERTY DEPARTMENT 4 EMBARCADERO CENTER			ART UNIT	PAPER NUMBER	
SUITE 3400			1615	1615	
SAN FRANCISCO, CA 94111			DATE MAILED: 09/23/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/656,657	BURKE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Micah-Paul Young	1615			
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	I36(a). In no event, however, may a reply be tin ly within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on	·				
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ☐ Claim(s) 1-14 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-14 are subject to restriction and/or	wn from consideration.				
Application Papers					
9)☐ The specification is objected to by the Examine	er.				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	• • • • • • • • • • • • • • • • • • • •	,			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)	_				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)				
2) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date		atent Application (PTO-152)			

Application/Control Number: 10/656,657 Page 2

Art Unit: 1615

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim 1, drawn to an oxidized collagen, classified in class 530, subclass 350.
  - II. Claims 2-5, drawn to a pharmaceutical formulation comprising a drug and collagen, classified in class 424, subclass 488.
  - III. Claims 6-14, drawn to a pharmaceutical formulation comprising a drug, collagen, and oxidized collagen, classified in class 424, subclass 488.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to separate inventions. The invention of group II is a pharmaceutical formulation requiring a drug, while the invention of group I is drawn to an oxidized collagen produce with no specific use, pharmaceutical or otherwise. Although the oxidized collagen of group I represents a possible species of the collagen of groups II and III, the inventions of groups II and III require drugs, while the collagen can be used in a food or cosmetic product.
- 3. Inventions II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the invention of group III requires an oxidized collagen while the invention of group

Application/Control Number: 10/656,657

Art Unit: 1615

II does not. The inventions are unrelated also due to the compatibility of certain pharmaceutical agents. The inclusion of oxidized collagen to the formulation of group III allows for a separate

and wider range of drugs useful in the formulation. These agents would not be compatible with

the formulation of group II, therefore the inventions of group II and II cannot be used together

and are unrelated.

4. Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art as shown by their different classification, restriction for examination

purposes as indicated is proper.

5. Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art because of their recognized divergent subject matter, restriction for

examination purposes as indicated is proper.

6. A telephone call was made to the attorney of record on 9/15/04 to request an oral election

to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608.

The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman K. Page can be reached on 571-272-0602. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/656,657

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young Examiner Art Unit 1615

MP Young

THURMAN K. PAGE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Page 4